Cetuximab Rechallenge Study

NCT ID: NCT01832467

Last Updated: 2020-06-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-24
• Study Completion Date: 2020-04-07

Brief Summary

To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with cetuximab-based chemotherapy for metastatic colorectal cancer (mCRC), but had stopped treatment for reasons other than disease progression.

Conditions

Metastatic Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

cetuximab-containing chemotherapy

• Cetuximab may be given at either one of the following schedules at the investigator's discretion:

1. 2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.

2. Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.

• Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.

Regimens to be combined with biweekly cetuximab:

1. Irinotecan at 2-weekly schedule.

2. FOLFIRI (as inpatient or via ambulatory pump).

3. FOLFOX (as inpatient or via ambulatory pump).

Group Type: EXPERIMENTAL

cetuximab-containing chemotherapy

Intervention Type: DRUG

Interventions

cetuximab-containing chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18 years or older.
• Able to give written informed consent.
• Histologically confirmed colorectal adenocarcinoma: must be either metastatic disease or unresectable recurrent disease.
• KRAS mutation status of the primary or metastastic CRC tumor must be wild-type.
• ECOG performance status of 0-1 at study entry.
• Must have measurable disease by RECIST (ver 1.1) criteria.
• Have progressive disease based on all of the following criteria (from a-d):

(a) Previously received cetuximab-based chemotherapy as first- or second-line treatment for metastatic or recurrent disease with, any one of the following drug combinations: (i) Cetuximab, fluoropyrimidines and oxaliplatin; or, (ii) Cetuximab, fluoropyrimidines and irinotecan; or (iii) Cetuximab and irinotecan. (b) Must have achieved at least stable disease, partial or complete response to treatment stated in '(a)' above.

(c) Experienced disease progression after more than 60 days from the last date of administration of the treatment stated in '(a)' above.

(d) 'Disease progression' can be defined as radiological or clinical progression.

• Adequate hematologic, renal, hepatic function as defined by: absolute neutrophil count >= 1.5 x 109/L, hemoglobin >= 9 g/L, platelets >= 100 x 109/L, calculated creatinine clearance >=55 ml/min, total bilirubin <= 2 x the upper limit of normal (ULN), alanine aminotransferase (ALT) <2.5 upper limit of normal or <= 5 x ULN in the presence of liver metastases.
• Must have recovered to grade 0-1 in severity, any toxicity related to previous cetuximab.

Exclusion Criteria

• Disease progression during first-line or second-line treatment with cetuximab and chemotherapy in combination.
• Patients who had prior cetuximab in BOTH first and second-line setting.
• Previous use of bevacizumab.
• Prior grade 3 to 4 hypersensitivity reaction to cetuximab.
• Clinically significant and poorly controlled medical illnesses within the last 6 months which may be exacerbated by study treatment.
• Estimated life expectancy of less than 3 months.
• Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before enrollment. Radiotherapy for pain relief is allowed as long as not targeted at an index or non-index lesion, e.g., bone metastases.
• Known brain and/or leptomeningeal metastases.
• Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias
• Pregnancy or lactation
• Previous malignancy other than colorectal cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix. The non-CRC malignancy must be in known complete remission for at least 5 years prior to enrollment.
• The presence of KRAS mutation in any of the CRC tumor tissue(s) - for example, patients with synchronous primary CRCs with different KRAS mutation status.
• Participants with reproductive potential who are unwilling to perform effective contraception.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chinese University of Hong Kong

OTHER

Sponsor Role: lead

Responsible Party

CCTU

Comprehensive Clinical Trial Unit

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Brigette MA, MD, FRCP

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Locations

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, , Hong Kong

Countries

Hong Kong

Other Identifiers

COL019

Identifier Type: -

Identifier Source: org_study_id